{"name":"US Neuropathy Centers","slug":"us-neuropathy-centers","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPUjhiMENhMnhlNWRhRHl5R2UydFEzOU13WVpvX3B4U3R2ajY0dTg4c0Nrd3Fxcjg3V2ZDVENlaVljOE5aeWlzYWU2a3FTRjlaOTFLNGl2dTdkUXozVVFzQjRSQ1hSRXhQemNtSE1fd2hUTDZ5TWtudHlZZnRaSVI5WElvcjRoRDdINDl6MEM4d1FXWVNKblpaYXI2djBpX2lfUzFkTVBUZWQ5RWZyUmJiTjFURVQ2cExhNEdxMk5yOA?oc=5","date":"2026-02-26","type":"pipeline","source":"AD HOC NEWS","summary":"Vertex Pharma Stock: Is Wall Street Too Cautious After The Neuropathy Surprise? - AD HOC NEWS","headline":"Vertex Pharma Stock: Is Wall Street Too Cautious After The Neuropathy Surprise?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQTHBHRnhRNEtpajNnZTV2OU8wVHlzVjFOM1pBc2ZLeUtsT0luV1hJZU0yWTM3TVVLOGQ5VDJ1R3IyTVVXLUpOMlpmalA3UFgwRTBHR0dESF9xNDlDTUhfc3NzTU9tdGRHbU5nYVJ1amRYTTR0UXRZRVY2UkJHVmZmNXBKU0hqR0M1SklvREdpOE93VjViNzFCZHB4bGpYMEE4b2N6UmFFeDJ0czlGT2JzZnJQbExkUU5HTDN5SWNoNHZSZzlLbWF2Rw?oc=5","date":"2025-07-30","type":"regulatory","source":"Psychiatric Times","summary":"FDA Clearance of IND for Ketamir-2, Novel Oral NMDA Receptor Antagonist for Neuropathic Pain - Psychiatric Times","headline":"FDA Clearance of IND for Ketamir-2, Novel Oral NMDA Receptor Antagonist for Neuropathic Pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9VVUJvUlZqVW9EQnJpS2Ewb1NXenQzQ3NUeWMwSHFWVVFlUmJWTHhpTXFXSzZBVWI4Q0d3bmVhOWZyUFc1VGJWUjZGMGZtV3FUaHp6T2lxRm45V0xTTXpsLVdyM1hYTzVIbHc?oc=5","date":"2025-02-21","type":"regulatory","source":"Yale Medicine","summary":"FDA Approves Non-Opioid Pain Medication Suzetrigine (Journavx™) - Yale Medicine","headline":"FDA Approves Non-Opioid Pain Medication Suzetrigine (Journavx™)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBrcnU1MXhSRjhrbndsWEhvc0FhQWtZMnJZUFZDWENMSW96Mk0yN3BJZTRYRUpqTGRQV2psNzR2YkRqYzQ2MHdmS0NoRHdFNjFFWl92c1l6a1lZTWJvOVhhRmREblFpXzJxZEYtOERjS3dVZw?oc=5","date":"2024-11-08","type":"trial","source":"Clinical Trials Arena","summary":"Averitas completes recruitment for trial of QUTENZA to treat post-surgical pain - Clinical Trials Arena","headline":"Averitas completes recruitment for trial of QUTENZA to treat post-surgical pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9JYTdRRU93dmRJeVY4NEVPN1VnUlJvNFVsa2JyRjk2ZjNyUE9fS3lMTFdubnNRb2VHVEc5TU1lQTJXR2F0Qkthd2tzSHlHMkxETjItLVZnVVA1eklmTlQyUzlqb0c5ZzBvUnBVeV9MenFYcnNPZlRoOEF3?oc=5","date":"2024-11-06","type":"pipeline","source":"Fortune Business Insights","summary":"Neuropathic Pain Market Size, Share | Global Report [2034] - Fortune Business Insights","headline":"Neuropathic Pain Market Size, Share | Global Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE83N1E0LTBSQzdZVkpjSzgzdWYxamxJdXZzQzVrSmh3N0RCVDFxRkdsR0x0NWJ5NTU3MjdUQ0JIWlIwdHR6TTgtb3pJek80dmlTVDZINmxmTXk2S1ZreGNqWEtMRkpIbGs?oc=5","date":"2023-05-29","type":"pipeline","source":"Market.us","summary":"Sensorimotor Neuropathy Market Top Competitor | CAGR of 5.9 % - Market.us","headline":"Sensorimotor Neuropathy Market Top Competitor | CAGR of 5.9 %","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNMjVUd01sVTNiTGZCaUo5d2VlRGxTXzYzbUpMN2tZOXAxUnNXWTNXYktFc0pXSHdtN2J2aWJYQU1pVUdEY1hxeDR5UWNnTVRqZnFJdVZKaGZ3QUhRdHJZMVZINXlGTFNhc1RiSnNCNFJZSUxUY29hb1JRVWEtMTdLaUd1SjNxaXdiNHRn?oc=5","date":"2021-02-12","type":"pipeline","source":"pharmaceutical-journal.com","summary":"Treatments for neuropathic pain - pharmaceutical-journal.com","headline":"Treatments for neuropathic pain - pharmaceutical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOWVpjbklWOUJTVFZjTTB6V3ZzVVlwWmYwSVk1anctWW5xUEFWODR0R056X004Z054X1lIRDZzYWpMSG5IdmNOTFMzLVpibDFkSFN0R29TVjVLZFU1RG5XVjl1LXNvWmpPMjhQUmpKdWRnVkpXU25uc2pvb1d2N3FWTV9BYk1DR2JHbU40X3V0Q0hRV1FZTkpKT1ZCelEzUEFUTTVpU2xNV0hCa2s0SmQ4?oc=5","date":"2018-11-14","type":"pipeline","source":"BioSpace","summary":"Grünenthal Snaps up Averitas Pharma for Undisclosed Sum to Extend Presence in the U.S. - BioSpace","headline":"Grünenthal Snaps up Averitas Pharma for Undisclosed Sum to Extend Presence in the U.S.","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}